brianajackson / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has handed victory to hedge fund manager Kyle Bass in an inter partes review (IPR) against a European healthcare company Fresenius Kabi-owned patent.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
USPTO, PTAB, IPR, patent, Kyle Bass, Diprivan, inter partes review, US Patent and Trademark Office, Fresenius Kabi